1
|
Javid H, Oryani MA, Rezagholinejad N, Hashemzadeh A, Karimi-Shahri M. Unlocking the potential of RGD-conjugated gold nanoparticles: a new frontier in targeted cancer therapy, imaging, and metastasis inhibition. J Mater Chem B 2024; 12:10786-10817. [PMID: 39351647 DOI: 10.1039/d4tb00281d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2024]
Abstract
In the rapidly evolving field of cancer therapeutics, the potential of gold nanoparticles (AuNPs) conjugated with RGD peptides has emerged as a promising avenue for targeted therapy and imaging. Despite numerous studies demonstrating the effectiveness of RGD-conjugated AuNPs in specifically targeting tumor cells and enhancing radiation therapy (RT), a comprehensive review of these advancements is currently lacking. This review aims to fill this critical gap in the literature. Our analysis reveals that RGD-conjugated AuNPs have shown significant promise in improving the diagnosis and treatment of various types of cancer, including breast cancer. However, the full potential of this technology is yet to be realized. The development of multifunctional nanoplatforms incorporating AuNPs has opened new horizons for targeted therapy, dual-mode imaging, and inhibition of tumor growth and metastasis. This review is of paramount importance as it provides a comprehensive overview of the current state of research in this area, and highlights the areas where further research is needed. It is hoped that this review will inspire further investigations into this promising nanotechnology, ultimately leading to improved cancer diagnosis and therapy. Therefore, the findings presented in this review underscore the potential of AuNPs conjugated with RGD peptides as a revolutionary approach in cancer therapeutics. It is our fervent hope that this review will serve as a catalyst for further research in this exciting field.
Collapse
Affiliation(s)
- Hossein Javid
- Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran
- Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Mahsa Akbari Oryani
- Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| | | | - Alireza Hashemzadeh
- Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
| | - Mehdi Karimi-Shahri
- Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Pathology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
| |
Collapse
|
2
|
Mahanta CS, Hansdah S, Khuntia K, Jena BB, Swain BR, Acharya S, Dash BP, Debata PR, Satapathy R. Novel carboranyl-BODIPY conjugates: design, synthesis and anti-cancer activity. RSC Adv 2024; 14:34643-34660. [PMID: 39479484 PMCID: PMC11521004 DOI: 10.1039/d4ra07241c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 10/23/2024] [Indexed: 11/02/2024] Open
Abstract
A series of four carboranyl-BODIPY conjugates (o-CB-10, m-CB-15, Me-o-CB-28, and Me-o-CB-35) and one phenylene-BODIPY conjugate (PB-20) were synthesized. The carboranyl-BODIPY conjugates incorporate boron clusters, specifically ortho- and meta-carboranes, covalently linked to BODIPY fluorophores while the phenylene-BODIPY conjugate features a phenylene ring covalently linked to BODIPY fluorophore. The newly synthesized conjugates were characterized by 1H NMR, 13C NMR, 11B NMR, 19F NMR, FT-IR, and high-resolution mass spectral analysis. In vitro cytotoxicity of the synthesized conjugates has been evaluated against the HeLa cervical cancer cell line. The study reveals that o-CB-10 shows a maximum cell death potential at lower concentrations (12.03 μM) and inhibited cell proliferation and migration in cancer (HeLa) cells. Additionally, flow cytometry study reveals that o-CB-10 and Me-o-CB-28 arrest the cell cycle at the S phase. The results indicate that the carboranyl-BODIPY conjugates have the potential to be effective anticancer agents.
Collapse
Affiliation(s)
| | - Sunitee Hansdah
- Department of Zoology Maharaja Sriram Chandra Bhanja Deo University Sri Ram Chandra Vihar, Takatpur, Mayurbhanj Baripada 757003 Odisha India
| | - Kabita Khuntia
- Department of Zoology Maharaja Sriram Chandra Bhanja Deo University Sri Ram Chandra Vihar, Takatpur, Mayurbhanj Baripada 757003 Odisha India
| | - Bibhuti Bhusan Jena
- Department of Chemistry Ravenshaw University College Square Cuttack 753003 Odisha India
| | - Biswa Ranjan Swain
- Department of Chemistry Ravenshaw University College Square Cuttack 753003 Odisha India
| | - Subhadeep Acharya
- Department of Chemistry Ravenshaw University College Square Cuttack 753003 Odisha India
| | | | - Priya Ranjan Debata
- Department of Zoology Maharaja Sriram Chandra Bhanja Deo University Sri Ram Chandra Vihar, Takatpur, Mayurbhanj Baripada 757003 Odisha India
| | - Rashmirekha Satapathy
- Department of Chemistry Ravenshaw University College Square Cuttack 753003 Odisha India
| |
Collapse
|
3
|
Yoshimoto M, Hayakawa T, Yamaguchi M, Kimura S, Fujii H. αvβ3 integrin-targeted magnetic resonance imaging in a pancreatic cancer mouse model using RGD-modified liposomes encapsulated with Fe-deferoxamine. PLoS One 2024; 19:e0310984. [PMID: 39316565 PMCID: PMC11421790 DOI: 10.1371/journal.pone.0310984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Accepted: 09/10/2024] [Indexed: 09/26/2024] Open
Abstract
Magnetic resonance (MR) imaging is a powerful imaging modality for obtaining anatomical information with high spatial and temporal resolution. In the drug delivery system (DDS) framework, nanoparticles such as liposomes are potential candidates for MR imaging. We validated that RGD peptides are possible targeting molecules for pancreatic cancer with αvβ3 integrin expression. This study aimed to evaluate RGD-modified liposomes loaded with ferrioxamine B for pancreatic cancer imaging. We synthesized four types of RGD-modified liposomes encapsulated with ferrioxamine B (SH-, H-, M-, and L-RGD-liposomes). The binding affinity of RGD-modified liposomes was evaluated in a competitive inhibition study using 125I-echistatin. To investigate the pharmacokinetics of RGD-modified liposomes, a biodistribution study using RGD-liposomes labeled with 111In was carried out in a human pancreatic cancer PANC-1 xenograft mouse model. Finally, MR was performed using ferrioxamine-B-loaded liposomes. RGD-liposomes inhibited the binding of 125I-echistatin to RGD. The biodistribution study revealed that 111In-RGD-liposomes accumulated significantly in the liver and spleen. Among the 111In-RGD-liposomes, 111In-H-RGD-liposomes showed the highest tumor-to-normal tissue ratio. In the MR study, H-RGD-liposomes loaded with ferrioxamine B showed higher tumor-to-muscle signal ratios than RKG-liposomes loaded with ferrioxamine B (control). We successfully synthesized RGD-liposomes that can target αvβ3 integrin.
Collapse
Affiliation(s)
- Mitsuyoshi Yoshimoto
- Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
| | - Takuya Hayakawa
- Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
| | - Masayuki Yamaguchi
- Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
| | - Sadaaki Kimura
- Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
| | - Hirofumi Fujii
- Division of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwa, Chiba, Japan
| |
Collapse
|
4
|
Lan G, Song Q, Luan Y, Cheng Y. Targeted strategies to deliver boron agents across the blood-brain barrier for neutron capture therapy of brain tumors. Int J Pharm 2024; 650:123747. [PMID: 38151104 DOI: 10.1016/j.ijpharm.2023.123747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/21/2023] [Accepted: 12/23/2023] [Indexed: 12/29/2023]
Abstract
Boron neutron capture therapy (BNCT), as an innovative radiotherapy technology, has demonstrated remarkable outcomes when compared to conventional treatments in the management of recurrent and refractory brain tumors. However, in BNCT of brain tumors, the blood-brain barrier is a main stumbling block for restricting the transport of boron drugs to brain tumors, while the tumor targeting and retention of boron drugs also affect the BNCT effect. This review focuses on the recent development of strategies for delivering boron drugs crossing the blood-brain barrier and targeting brain tumors, providing new insights for the development of efficient boron drugs for the treatment of brain tumors.
Collapse
Affiliation(s)
- Gongde Lan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Qingxu Song
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China
| | - Yuxia Luan
- Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
| | - Yufeng Cheng
- Department of Radiation Oncology, Boron Neutron Capture Therapy Medical Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
| |
Collapse
|
5
|
Marforio TD, Carboni A, Calvaresi M. In Vivo Application of Carboranes for Boron Neutron Capture Therapy (BNCT): Structure, Formulation and Analytical Methods for Detection. Cancers (Basel) 2023; 15:4944. [PMID: 37894311 PMCID: PMC10605826 DOI: 10.3390/cancers15204944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/22/2023] [Accepted: 10/09/2023] [Indexed: 10/29/2023] Open
Abstract
Carboranes have emerged as one of the most promising boron agents in boron neutron capture therapy (BNCT). In this context, in vivo studies are particularly relevant, since they provide qualitative and quantitative information about the biodistribution of these molecules, which is of the utmost importance to determine the efficacy of BNCT, defining their localization and (bio)accumulation, as well as their pharmacokinetics and pharmacodynamics. First, we gathered a detailed list of the carboranes used for in vivo studies, considering the synthesis of carborane derivatives or the use of delivery system such as liposomes, micelles and nanoparticles. Then, the formulation employed and the cancer model used in each of these studies were identified. Finally, we examined the analytical aspects concerning carborane detection, identifying the main methodologies applied in the literature for ex vivo and in vivo analysis. The present work aims to identify the current strengths and weakness of the use of carboranes in BNCT, establishing the bottlenecks and the best strategies for future applications.
Collapse
Affiliation(s)
| | - Andrea Carboni
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| | - Matteo Calvaresi
- Dipartimento di Chimica “Giacomo Ciamician”, Alma Mater Studiorum—Università di Bologna, Via Francesco Selmi 2, 40126 Bologna, Italy;
| |
Collapse
|
6
|
Oloo SO, Smith KM, Vicente MDGH. Multi-Functional Boron-Delivery Agents for Boron Neutron Capture Therapy of Cancers. Cancers (Basel) 2023; 15:3277. [PMID: 37444386 DOI: 10.3390/cancers15133277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Revised: 06/03/2023] [Accepted: 06/19/2023] [Indexed: 07/15/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer treatment that involves the irradiation of 10B-containing tumors with low-energy neutrons (thermal or epithermal). The alpha particles and recoiling Li nuclei that are produced in the 10B-capture nuclear reaction are high-linear-energy transfer particles that destroy boron-loaded tumor cells; therefore, BNCT has the potential to be a localized therapeutic modality. Two boron-delivery agents have been used in clinical trials of BNCT in patients with malignant brain tumors, cutaneous melanoma, or recurrent tumors of the head and neck region, demonstrating the potential of BNCT in the treatment of difficult cancers. A variety of potentially highly effective boron-delivery agents have been synthesized in the past four decades and tested in cells and animal models. These include boron-containing nucleosides, peptides, proteins, polyamines, porphyrins, liposomes, monoclonal antibodies, and nanoparticles of various types. The most promising agents are multi-functional boronated molecules and nanoparticles functionalized with tumor cell-targeting moieties that increase their tumor selectivity and contain a radiolabel or fluorophore to allow quantification of 10B-biodistribution and treatment planning. This review discusses multi-functional boron agents reported in the last decade, but their full potential can only be ascertained after their evaluation in BNCT clinical trials.
Collapse
Affiliation(s)
- Sebastian O Oloo
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | - Kevin M Smith
- Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA
| | | |
Collapse
|
7
|
Seneviratne DS, Saifi O, Mackeyev Y, Malouff T, Krishnan S. Next-Generation Boron Drugs and Rational Translational Studies Driving the Revival of BNCT. Cells 2023; 12:1398. [PMID: 37408232 DOI: 10.3390/cells12101398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 04/26/2023] [Accepted: 05/04/2023] [Indexed: 07/07/2023] Open
Abstract
BNCT is a high-linear-energy transfer therapy that facilitates tumor-directed radiation delivery while largely sparing adjacent normal tissues through the biological targeting of boron compounds to tumor cells. Tumor-specific accumulation of boron with limited accretion in normal cells is the crux of successful BNCT delivery. Given this, developing novel boronated compounds with high selectivity, ease of delivery, and large boron payloads remains an area of active investigation. Furthermore, there is growing interest in exploring the immunogenic potential of BNCT. In this review, we discuss the basic radiobiological and physical aspects of BNCT, traditional and next-generation boron compounds, as well as translational studies exploring the clinical applicability of BNCT. Additionally, we delve into the immunomodulatory potential of BNCT in the era of novel boron agents and examine innovative avenues for exploiting the immunogenicity of BNCT to improve outcomes in difficult-to-treat malignancies.
Collapse
Affiliation(s)
| | - Omran Saifi
- Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA
| | - Yuri Mackeyev
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| | - Timothy Malouff
- Department of Radiation Oncology, University of Oklahoma, Oklahoma City, OK 73019, USA
| | - Sunil Krishnan
- Department of Neurosurgery, UTHealth, Houston, TX 77030, USA
| |
Collapse
|
8
|
Laird M, Matsumoto K, Higashi Y, Komatsu A, Raitano A, Morrison K, Suzuki M, Tamanoi F. Organosilica nanoparticles containing sodium borocaptate (BSH) provide new prospects for boron neutron capture therapy (BNCT): efficient cellular uptake and enhanced BNCT efficacy. NANOSCALE ADVANCES 2023; 5:2537-2546. [PMID: 37143818 PMCID: PMC10153076 DOI: 10.1039/d2na00839d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Accepted: 03/20/2023] [Indexed: 05/06/2023]
Abstract
Boron neutron capture therapy (BNCT), a method based on the fission of boron-10 upon neutron irradiation, has emerged as an attractive option for radiation therapy. To date, the main drugs used in BNCT are 4-boronophenylalanine (BPA) and sodium borocaptate (BSH). While BPA has been extensively tested in clinical trials, the use of BSH has been limited, mainly due to its poor cellular uptake. Here, we describe a novel type of mesoporous silica-based nanoparticle containing BSH covalently attached to a nanocarrier. Synthesis and characterization of these nanoparticles (BSH-BPMO) are presented. The synthetic strategy involves a click thiol-ene reaction with the boron cluster, providing hydrolytically stable linkage with the BSH in four steps. The BSH-BPMO nanoparticles were efficiently taken up into cancer cells and accumulated in the perinuclear region. Inductively coupled plasma (ICP) measurements of boron uptake in cells highlight the important role of the nanocarrier in the enhancement of boron internalization. BSH-BPMO nanoparticles were also taken up and distributed throughout tumour spheroids. BNCT efficacy was examined by the neutron exposure of the tumour spheroids. BSH-BPMO loaded spheroids were completely destroyed upon neutron irradiation. In contrast, neutron irradiation of tumour spheroids loaded with BSH or BPA resulted in significantly less spheroid shrinkage. The significant difference in BNCT efficacy of the BSH-BPMO was correlated with the improved boron uptake via the nanocarrier. Overall, these results demonstrate the critical role of the nanocarrier in BSH internalization and the enhanced BNCT efficacy of the BSH-BPMO compared with BSH and BPA, two drugs used in BNCT clinical trials.
Collapse
Affiliation(s)
- Mathilde Laird
- Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University Kyoto 606-8501 Japan
| | - Kotaro Matsumoto
- Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University Kyoto 606-8501 Japan
| | - Yuya Higashi
- Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University Kyoto 606-8501 Japan
| | - Aoi Komatsu
- Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University Kyoto 606-8501 Japan
| | - Art Raitano
- TAE Life Sciences, Drug Development Division Santa Monica CA 90404 USA
| | - Kendall Morrison
- TAE Life Sciences, Drug Development Division Santa Monica CA 90404 USA
| | - Minoru Suzuki
- Institute for Integrated Radiation and Nuclear Science, Kyoto University Kumatori 590-0494 Japan
| | - Fuyuhiko Tamanoi
- Institute for Integrated Cell-Material Sciences, Institute for Advanced Study, Kyoto University Kyoto 606-8501 Japan
- Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles USA
| |
Collapse
|
9
|
Vakhrushev AV, Gruzdev DA, Demin AM, Levit GL, Krasnov VP. Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide. Molecules 2023; 28:molecules28083467. [PMID: 37110700 PMCID: PMC10143838 DOI: 10.3390/molecules28083467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 04/07/2023] [Accepted: 04/12/2023] [Indexed: 04/29/2023] Open
Abstract
Short peptides containing the Arg-Gly-Asp (RGD) fragment can selectively bind to integrins on the surface of tumor cells and are attractive transport molecules for the targeted delivery of therapeutic and diagnostic agents to tumors (for example, glioblastoma). We have demonstrated the possibility of obtaining the N- and C-protected RGD peptide containing 3-amino-closo-carborane and a glutaric acid residue as a linker fragment. The resulting carboranyl derivatives of the protected RGD peptide are of interest as starting compounds in the synthesis of unprotected or selectively protected peptides, as well as building blocks for preparation of boron-containing derivatives of the RGD peptide of a more complex structure.
Collapse
Affiliation(s)
- Alexander V Vakhrushev
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Dmitry A Gruzdev
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Alexander M Demin
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Galina L Levit
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| | - Victor P Krasnov
- Postovsky Institute of Organic Synthesis, Russian Academy of Sciences (Ural Branch), 620108 Ekaterinburg, Russia
| |
Collapse
|
10
|
Beck-Sickinger AG, Becker DP, Chepurna O, Das B, Flieger S, Hey-Hawkins E, Hosmane N, Jalisatgi SS, Nakamura H, Patil R, Vicente MDGH, Viñas C. New Boron Delivery Agents. Cancer Biother Radiopharm 2023; 38:160-172. [PMID: 36350709 PMCID: PMC10325817 DOI: 10.1089/cbr.2022.0060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
This proceeding article compiles current research on the development of boron delivery drugs for boron neutron capture therapy that was presented and discussed at the National Cancer Institute (NCI) Workshop on Neutron Capture Therapy that took place on April 20-22, 2022. The most used boron sources are icosahedral boron clusters attached to peptides, proteins (such as albumin), porphyrin derivatives, dendrimers, polymers, and nanoparticles, or encapsulated into liposomes. These boron clusters and/or carriers can be labeled with contrast agents allowing for the use of imaging techniques, such as PET, SPECT, and fluorescence, that enable quantification of tumor-localized boron and their use as theranostic agents.
Collapse
Affiliation(s)
| | - Daniel P. Becker
- Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois, USA
| | - Oksana Chepurna
- Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Bhaskar Das
- Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York, USA
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Surgery, Weill Cornell Medical College of Cornell University, New York, New York, USA
| | - Sebastian Flieger
- Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, Illinois, USA
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Leipzig, Germany
| | - Narayan Hosmane
- Department of Chemistry & Biochemistry, Northern Illinois University, DeKalb, Illinois, USA
| | | | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan
| | - Rameshwar Patil
- Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | | | - Clara Viñas
- Institut de Ciencia de Materials de Barcelona, ICMAB-CSIC, Campus UAB, Bellaterra, Spain
| |
Collapse
|
11
|
Mishiro K, Imai S, Ematsu Y, Hirose K, Fuchigami T, Munekane M, Kinuya S, Ogawa K. RGD Peptide-Conjugated Dodecaborate with the Ga-DOTA Complex: A Preliminary Study for the Development of Theranostic Agents for Boron Neutron Capture Therapy and Its Companion Diagnostics. J Med Chem 2022; 65:16741-16753. [PMID: 36512639 DOI: 10.1021/acs.jmedchem.2c01586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A boron neutron capture therapy (BNCT) system, using boron-10-introduced agents coupled with companion diagnostics, is anticipated as a promising cancer theranostic. Thus, this study aimed to synthesize and evaluate a probe closo-dodecaborate-(Ga-DOTA)-c(RGDfK) (16) [Ga = gallium, DOTA =1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, and c(RGDfK) = cyclo(arginine-glycine-aspartate-d-phenylalanine-lysine] containing closo-dodecaborate ([B12H12]2-) as a boron cluster, a [67Ga]Ga-DOTA derivative for nuclear medicine imaging, and an RGD peptide for tumor targeting. Moreover, we prepared a radioiodinated probe [125I]17 in which I-125 is introduced into a closo-dodecaborate moiety of 16. [67Ga]16 and [125I]17 showed high stability and high uptake in cancer cells in vitro. Biodistribution experiments in tumor-bearing mice revealed similar biodistribution patterns between [67Ga]16 and [125I]17, such as a high uptake in the tumor and a low uptake in other non-target tissues. Meanwhile, [125I]17 exhibited higher accumulation in most tissues, including the tumor, than [67Ga]16, probably because of higher albumin binding. The higher the [125I]17 accumulation in the tumor, the more desirable it is for BNCT, with the possibility that the iodo-closo-dodecaborate site may work as an albumin binder.
Collapse
Affiliation(s)
- Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa920-1192, Japan
| | - Sayaka Imai
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa920-1192, Japan
| | - Yuki Ematsu
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa920-1192, Japan
| | - Katsumi Hirose
- Southern Tohoku BNCT Research Center, Koriyama963-8052, Japan
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa920-1192, Japan
| | - Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kanazawa920-1192, Japan
| | - Seigo Kinuya
- Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University, Takara-machi 13-1, Kanazawa, Ishikawa920-8641, Japan
| | - Kazuma Ogawa
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa920-1192, Japan.,Graduate School of Medical Sciences, Kanazawa University, Kanazawa920-1192, Japan
| |
Collapse
|
12
|
Reaction of Chloroacetyl-Modified Peptides with Mercaptoundecahydrododecaborate (BSH) Is Accelerated by Basic Amino Acid Residues in the Peptide. Processes (Basel) 2022. [DOI: 10.3390/pr10112200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We assessed a reactivity of chloroacetyl-modified tripeptides consisting of various amino acid residues (Cl-3X) and mercaptoundecahydrododecaborate (BSH) by converting Cl-3X to its reactant (BS-3X). We showed that the Cl-3X consisting of basic amino acid residues (e.g., Arg) reacted with BSH effectively and its conversion decreased as the number of Arg residues in the Cl-3X decreased. Furthermore, a reactivity of the peptides with introduction of an alkyl linker between the triarginine and the chloroacetyl group (Cl-Cn-3R) with BSH decreased with increasing alkyl linker length. These results indicate that an electrostatic attraction of positively charged amino acid residues in the tripeptides and negatively charged BSH causes BSH to gather in a vicinity of the chloroacetyl group, resulting in an accelerated reaction. This work should aid a development of new boron agents using BSH in boron neutron capture therapy.
Collapse
|
13
|
Li F, Luo Z. Boron delivery agents for boron neutron capture therapy. CHINESE SCIENCE BULLETIN-CHINESE 2021. [DOI: 10.1360/tb-2021-1013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
14
|
Quan H, Fan L, Huang Y, Xia X, He Y, Liu S, Yu J. Hyaluronic acid-decorated carborane-TAT conjugation nanomicelles: A potential boron agent with enhanced selectivity of tumor cellular uptake. Colloids Surf B Biointerfaces 2021; 204:111826. [PMID: 33984611 DOI: 10.1016/j.colsurfb.2021.111826] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/27/2021] [Accepted: 05/04/2021] [Indexed: 11/28/2022]
Abstract
Boron neutron capture therapy (BNCT) has received widespread attention as a new type of radiation therapy. The main problem encountered in BNCT is insufficient tumor cellular uptake of boron agents. In this study, cell-penetrating peptide TAT-conjugated o-carborane was synthesized. The conjugation can self-assemble to form positively charged carborane-TAT micelles, and then adsorb negatively charged hyaluronic acid (HA) to give core-shell structured carborane-TAT@HA micelles. Carborane-TAT@HA micelles exhibits a large amount of boron uptake at the tumor tissue through the enhanced permeability and retention (EPR) effect and the ability of HA to bind to CD44 receptors. Carborane-TAT@HA was wrapped by the HA shell during systemic circulation to avoid non-specific uptake of TAT with normal cells, while tumor microenvironment-responsive shedding of HA shell could expose Carborane-TAT to penetrate the cell membrane into tumor cells. Experiments have proved the enhanced selectivity of tumor cellular uptake of the boron drug, displayed excellent drug delivery potential, and can meet the basic requirements of BNCT.
Collapse
Affiliation(s)
- Hao Quan
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Li Fan
- Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, PR China
| | - Yushu Huang
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Xiaoyan Xia
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Yang He
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China
| | - Shiyuan Liu
- Department of Radiology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, PR China.
| | - Jiahui Yu
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200062, PR China.
| |
Collapse
|
15
|
Gruzdev DA, Levit GL, Krasnov VP, Charushin VN. Carborane-containing amino acids and peptides: Synthesis, properties and applications. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213753] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
16
|
Telegina AA, Gruzdev DA, Levit GL, Krasnov VP. Synthesis of a novel planar-chiral nido-carborane amino acid. Russ Chem Bull 2021. [DOI: 10.1007/s11172-021-3121-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
17
|
Kalot G, Godard A, Busser B, Pliquett J, Broekgaarden M, Motto-Ros V, Wegner KD, Resch-Genger U, Köster U, Denat F, Coll JL, Bodio E, Goze C, Sancey L. Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications. Cells 2020; 9:cells9091953. [PMID: 32854219 PMCID: PMC7565158 DOI: 10.3390/cells9091953] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 08/18/2020] [Accepted: 08/20/2020] [Indexed: 12/16/2022] Open
Abstract
Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on the nuclear capture of slow neutrons by stable 10B atoms followed by charged particle emission that inducing extensive damage on a very localized level (<10 μm). To be efficient, a sufficient amount of 10B should accumulate in the tumor area while being almost cleared from the normal surroundings. A water-soluble aza-boron-dipyrromethene dyes (BODIPY) fluorophore was reported to strongly accumulate in the tumor area with high and BNCT compatible Tumor/Healthy Tissue ratios. The clinically used 10B-BSH (sodium borocaptate) was coupled to the water-soluble aza-BODIPY platform for enhanced 10B-BSH tumor vectorization. We demonstrated a strong uptake of the compound in tumor cells and determined its biodistribution in mice-bearing tumors. A model of chorioallantoic membrane-bearing glioblastoma xenograft was developed to evidence the BNCT potential of such compound, by subjecting it to slow neutrons. We demonstrated the tumor accumulation of the compound in real-time using optical imaging and ex vivo using elemental imaging based on laser-induced breakdown spectroscopy. The tumor growth was significantly reduced as compared to BNCT with 10B-BSH. Altogether, the fluorescent aza-BODIPY/10B-BSH compound is able to vectorize and image the 10B-BSH in the tumor area, increasing its theranostic potential for efficient approach of BNCT.
Collapse
Affiliation(s)
- Ghadir Kalot
- Institute for Advanced Biosciences, UGA INSERM U1209 CNRS UMR5309, 38700 La Tronche, France; (G.K.); (B.B.); (M.B.); (J.-L.C.)
| | - Amélie Godard
- Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université Bourgogne Franche-Comté, 21078 Dijon, France; (A.G.); (J.P.); (F.D.)
| | - Benoît Busser
- Institute for Advanced Biosciences, UGA INSERM U1209 CNRS UMR5309, 38700 La Tronche, France; (G.K.); (B.B.); (M.B.); (J.-L.C.)
- Grenoble Alpes University Hospital, 38043 Grenoble, France
| | - Jacques Pliquett
- Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université Bourgogne Franche-Comté, 21078 Dijon, France; (A.G.); (J.P.); (F.D.)
| | - Mans Broekgaarden
- Institute for Advanced Biosciences, UGA INSERM U1209 CNRS UMR5309, 38700 La Tronche, France; (G.K.); (B.B.); (M.B.); (J.-L.C.)
| | - Vincent Motto-Ros
- Institut Lumière Matière UMR 5306, Université Lyon 1-CNRS, Université de Lyon, 69622 Villeurbanne, France;
| | - Karl David Wegner
- Division Biophotonics, Federal Institute for Materials Research and Testing (BAM), Richard-Willstaetter-Str. 11, 12489 Berlin, Germany; (K.D.W.); (U.R.-G.)
| | - Ute Resch-Genger
- Division Biophotonics, Federal Institute for Materials Research and Testing (BAM), Richard-Willstaetter-Str. 11, 12489 Berlin, Germany; (K.D.W.); (U.R.-G.)
| | - Ulli Köster
- Institut Laue Langevin, 38042 Grenoble, France;
| | - Franck Denat
- Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université Bourgogne Franche-Comté, 21078 Dijon, France; (A.G.); (J.P.); (F.D.)
| | - Jean-Luc Coll
- Institute for Advanced Biosciences, UGA INSERM U1209 CNRS UMR5309, 38700 La Tronche, France; (G.K.); (B.B.); (M.B.); (J.-L.C.)
| | - Ewen Bodio
- Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université Bourgogne Franche-Comté, 21078 Dijon, France; (A.G.); (J.P.); (F.D.)
- Correspondence: (E.B.); (C.G.); (L.S.); Tel.: +33-380-396-076 (E.B.); +33-380-399-043 (C.G.); +33-476-549-410 (L.S.)
| | - Christine Goze
- Institut de Chimie Moléculaire de l’Université de Bourgogne, ICMUB CNRS, UMR 6302, Université Bourgogne Franche-Comté, 21078 Dijon, France; (A.G.); (J.P.); (F.D.)
- Correspondence: (E.B.); (C.G.); (L.S.); Tel.: +33-380-396-076 (E.B.); +33-380-399-043 (C.G.); +33-476-549-410 (L.S.)
| | - Lucie Sancey
- Institute for Advanced Biosciences, UGA INSERM U1209 CNRS UMR5309, 38700 La Tronche, France; (G.K.); (B.B.); (M.B.); (J.-L.C.)
- Correspondence: (E.B.); (C.G.); (L.S.); Tel.: +33-380-396-076 (E.B.); +33-380-399-043 (C.G.); +33-476-549-410 (L.S.)
| |
Collapse
|
18
|
Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020; 8:571. [PMID: 32733853 PMCID: PMC7359416 DOI: 10.3389/fchem.2020.00571] [Citation(s) in RCA: 142] [Impact Index Per Article: 35.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.
Collapse
Affiliation(s)
- Paul Hoppenz
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | | |
Collapse
|
19
|
Worm DJ, Els‐Heindl S, Beck‐Sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Pept Sci (Hoboken) 2020. [DOI: 10.1002/pep2.24171] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Dennis J. Worm
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | - Sylvia Els‐Heindl
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | | |
Collapse
|
20
|
|
21
|
Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Lerchen HG, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. J Org Chem 2019; 85:1446-1457. [PMID: 31813224 DOI: 10.1021/acs.joc.9b02406] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Boron neutron capture therapy (BNCT) allows the selective elimination of malignant tumor cells without affecting healthy tissue. Although this binary radiotherapy approach has been known for decades, BNCT failed to reach the daily clinics to date. One of the reasons is the lack of selective boron delivery agents. Using boron loaded peptide conjugates, which address G protein-coupled receptors overexpressed on tumor cells allow the intracellular accumulation of boron. The gastrin-releasing peptide receptor (GRPR) is a well-known target in cancer diagnosis and can potentially be used for BNCT. Here, we present the successful introduction of multiple bis-deoxygalactosyl-carborane building blocks to the GRPR-selective ligand [d-Phe6, β-Ala11, Ala13, Nle14]Bn(6-14) (sBB2L) generating peptide conjugates with up to 80 boron atoms per molecule. Receptor activation was retained, metabolic stability was increased, and uptake into PC3 cells was proven without showing any intrinsic cytotoxicity. Furthermore, undesired uptake into liver cells was suppressed by using l-deoxygalactosyl modified carborane building blocks. Due to its high boron loading and excellent GRPR selectivity, this conjugate can be considered as a promising boron delivery agent for BNCT.
Collapse
Affiliation(s)
- Paul Hoppenz
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | | | | | - Bernd Riedl
- Bayer AG , Aprather Weg 18A , Wuppertal , Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Annette G Beck-Sickinger
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| |
Collapse
|
22
|
Li R, Zhang J, Guo J, Xu Y, Duan K, Zheng J, Wan H, Yuan Z, Chen H. Application of Nitroimidazole-Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy. Mol Pharm 2019; 17:202-211. [PMID: 31763850 DOI: 10.1021/acs.molpharmaceut.9b00898] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Boron neutron capture therapy (BNCT) has received extensive attention as noninvasive cell-level oncotherapy for treating solid cancer tumors. However, boron-containing drugs such as l-boronophenylalanine (BPA) and sodium borocaptate have low boron content and/or poor tumor-targeting ability, limiting their application. In this study, we designed and synthesized a series of nontoxic, dual-target boron carriers (B139, B142, and B151) with the ability to accumulate specifically in tumor cells. We found that the B139 uptake into hypoxic tumor regions was high, with a 70-fold boron content compared to BPA. In addition, in vivo observation showed that B139 can be trapped in tumor cells for a prolonged period and maintains an effective therapeutic concentration, with a peak boron concentration of 50.7 μg/g and a high tumor: blood boron ratio of >3, achieving ideal BNCT conditions. Cytotoxicity evaluation in mice further proved that B139 is safe and reliable. Therefore, B139 has great potential for BNCT application as a dual-target, safe, and efficient boron carrier.
Collapse
Affiliation(s)
- Ruixi Li
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Juanjuan Zhang
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Jingxuan Guo
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Yue Xu
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Kunyuan Duan
- Department of Pharmacy , Qujing Medical College , Qujing 655000 , China
| | - Jinrong Zheng
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Hao Wan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Zhenwei Yuan
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| | - Haiyan Chen
- Department of Biomedical Engineering, School of Engineering, State Key Laboratory of Natural Medicines , China Pharmaceutical University , 24 Tongjia Lane , Gulou District, Nanjing 210009 , China
| |
Collapse
|
23
|
Isono A, Tsuji M, Sanada Y, Matsushita A, Masunaga S, Hirayama T, Nagasawa H. Design, Synthesis, and Evaluation of Lipopeptide Conjugates of Mercaptoundecahydrododecaborate for Boron Neutron Capture Therapy. ChemMedChem 2019; 14:823-832. [DOI: 10.1002/cmdc.201800793] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2018] [Revised: 01/23/2019] [Indexed: 12/26/2022]
Affiliation(s)
- Aoi Isono
- Laboratory of Pharmaceutical and Medicinal ChemistryGifu Pharmaceutical University Daigaku-nishi 1-25-4 Gifu-city Gifu 501-1196 Japan
| | - Mieko Tsuji
- Laboratory of Pharmaceutical and Medicinal ChemistryGifu Pharmaceutical University Daigaku-nishi 1-25-4 Gifu-city Gifu 501-1196 Japan
| | - Yu Sanada
- Particle Radiation BiologyInstitute for Integrated Radiation and Nuclear ScienceKyoto University 2-1010 Asashiro-Nishi Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Akari Matsushita
- Laboratory of Pharmaceutical and Medicinal ChemistryGifu Pharmaceutical University Daigaku-nishi 1-25-4 Gifu-city Gifu 501-1196 Japan
| | - Shinichiro Masunaga
- Particle Radiation BiologyInstitute for Integrated Radiation and Nuclear ScienceKyoto University 2-1010 Asashiro-Nishi Kumatori-cho, Sennan-gun Osaka 590-0494 Japan
| | - Tasuku Hirayama
- Laboratory of Pharmaceutical and Medicinal ChemistryGifu Pharmaceutical University Daigaku-nishi 1-25-4 Gifu-city Gifu 501-1196 Japan
| | - Hideko Nagasawa
- Laboratory of Pharmaceutical and Medicinal ChemistryGifu Pharmaceutical University Daigaku-nishi 1-25-4 Gifu-city Gifu 501-1196 Japan
| |
Collapse
|
24
|
Goszczyński TM, Fink K, Boratyński J. Icosahedral boron clusters as modifying entities for biomolecules. Expert Opin Biol Ther 2019; 18:205-213. [PMID: 30063861 DOI: 10.1080/14712598.2018.1473369] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
INTRODUCTION Icosahedral boron clusters have unique properties useful in medicinal chemistry: rigidity, chemical stability, and three-dimensional aromaticity. Furthermore, these abiotic compounds have low toxicity and are stable in the biological environment. All these features ultimately give them the ability to interact with biological molecules in a different mode than organic compounds. AREAS COVERED In the present article, we aim to introduce boron clusters as a class of entities suitable for modifications of biomolecules to obtain a specific biological effect. We will focus on icosahedral boron clusters, as well as metallacarboranes, and their biological activity and interaction with the biological environment. EXPERT OPINION Boron clusters are suitable for altering structural and functional features of biomolecules and can be used in the development of new drugs and drug delivery systems. The high affinity of boron clusters, especially metallacarboranes, to albumin creates a new possibility to use them to optimize the pharmacokinetics of biologically active peptides. Boron clusters have high potential in biological and medicinal applications. Due to their peculiar properties, they can be used to optimize parameters critical for the biological activity of therapeutic substances and their affinity toward biological targets.
Collapse
Affiliation(s)
- Tomasz M Goszczyński
- a Laboratory of Biomedical Chemistry, Department of Experimental Oncology , Hirszfeld Institute of Immunology and Experimental Therapy, PAS , Wrocław , Poland
| | - Krzysztof Fink
- a Laboratory of Biomedical Chemistry, Department of Experimental Oncology , Hirszfeld Institute of Immunology and Experimental Therapy, PAS , Wrocław , Poland
| | - Janusz Boratyński
- a Laboratory of Biomedical Chemistry, Department of Experimental Oncology , Hirszfeld Institute of Immunology and Experimental Therapy, PAS , Wrocław , Poland
| |
Collapse
|
25
|
Gruzdev DA, Ustinova VO, Levit GL, Ol’shevskaya VA, Krasnov VP. Synthesis of meta-Carboranyl-(S)-homocysteine Sulfoxide. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2018. [DOI: 10.1134/s1070428018100251] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
26
|
Yamagami M, Tajima T, Ishimoto K, Miyake H, Michiue H, Takaguchi Y. Physical modification of carbon nanotubes with a dendrimer bearing terminal mercaptoundecahydrododecaborates (Na
2
B
12
H
11
S). HETEROATOM CHEMISTRY 2018. [DOI: 10.1002/hc.21467] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Masahiro Yamagami
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Tomoyuki Tajima
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Kango Ishimoto
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| | - Hideaki Miyake
- Graduate School of Sciences and Technology for InnovationYamaguchi University Yamaguchi Japan
| | | | - Yutaka Takaguchi
- Graduate School of Environmental and Life ScienceOkayama University Okayama Japan
| |
Collapse
|
27
|
Fink K, Kobak K, Kasztura M, Boratyński J, Goszczyński TM. Synthesis and Biological Activity of Thymosin β4-Anionic Boron Cluster Conjugates. Bioconjug Chem 2018; 29:3509-3515. [DOI: 10.1021/acs.bioconjchem.8b00646] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Krzysztof Fink
- Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy PAS, 12 Rudolf Weigl Street, 53-114 Wrocław, Poland
| | - Kamil Kobak
- Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wrocław Medical University, 5 Rudolf Weigl Street, 50-981 Wrocław, Poland
| | - Monika Kasztura
- Laboratory for Applied Research on Cardiovascular System, Department of Heart Diseases, Wrocław Medical University, 5 Rudolf Weigl Street, 50-981 Wrocław, Poland
| | - Janusz Boratyński
- Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy PAS, 12 Rudolf Weigl Street, 53-114 Wrocław, Poland
| | - Tomasz M. Goszczyński
- Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy PAS, 12 Rudolf Weigl Street, 53-114 Wrocław, Poland
| |
Collapse
|
28
|
Yinghuai Z, Lin X, Xie H, Li J, Hosmane NS, Zhang Y. The Current Status and Perspectives of Delivery Strategy for Boron-based Drugs. Curr Med Chem 2018; 26:5019-5035. [PMID: 30182851 DOI: 10.2174/0929867325666180904105212] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 07/26/2018] [Accepted: 07/27/2018] [Indexed: 12/27/2022]
Abstract
Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.
Collapse
Affiliation(s)
- Zhu Yinghuai
- School of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa 999078, Macau. Macao
| | - Xinglong Lin
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Hongming Xie
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Jianlin Li
- HEC Research and Development Center, Dongguan 523871. China
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois 60115-2862. United States
| | - Yingjun Zhang
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| |
Collapse
|
29
|
Worm DJ, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Koebberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. J Pept Sci 2018; 24:e3119. [PMID: 30168238 DOI: 10.1002/psc.3119] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 07/18/2018] [Accepted: 07/19/2018] [Indexed: 12/26/2022]
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer therapy, which combines the biochemical targeting of a boron-containing drug with the regional localization of radiation treatment. Although the concept of BNCT has been known for decades, the selective delivery of boron into tumor cells remains challenging. G protein-coupled receptors that are overexpressed on cancer cells in combination with peptidic ligands can be potentially used as shuttle system for a tumor-directed boron uptake. In this study, we present the generation of short, boron-rich peptide conjugates that target the ghrelin receptor. Expression of the ghrelin receptor on various cancer cells makes it a viable target for BNCT. We designed a novel hexapeptide super-agonist that was modified with different specifically synthesized carborane monoclusters and tested for ghrelin receptor activation. A meta-carborane building block with a mercaptoacetic acid linker was found to be optimal for peptide modification, owing to its chemical stability and a suitable activation efficacy of the conjugate. The versatility of this carborane for the development of peptidic boron delivery agents was further demonstrated by the generation of highly potent, boron-loaded conjugates using the backbone of the known ghrelin receptor ligands growth hormone releasing peptide 6 and Ipamorelin.
Collapse
Affiliation(s)
- Dennis J Worm
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| | - Martin Kellert
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Robert Kuhnert
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Stefan Saretz
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | | | - Bernd Riedl
- Bayer AG, Aprather Weg 18A, 42113, Wuppertal, Germany
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Annette G Beck-Sickinger
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| |
Collapse
|
30
|
Feng C, Zhang H, Yang J, Chen G. A novel approach to ortho-carborane by decarboranylation of 1-(isopropyl benzoate)-1,2-dicarba-closo-dodecaborane. Tetrahedron Lett 2015. [DOI: 10.1016/j.tetlet.2015.03.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Goszczyński TM, Kowalski K, Leśnikowski ZJ, Boratyński J. Solid state, thermal synthesis of site-specific protein-boron cluster conjugates and their physicochemical and biochemical properties. Biochim Biophys Acta Gen Subj 2014; 1850:411-8. [PMID: 25445715 DOI: 10.1016/j.bbagen.2014.11.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Revised: 11/07/2014] [Accepted: 11/14/2014] [Indexed: 12/25/2022]
Abstract
BACKGROUND Boron clusters represent a vast family of boron-rich compounds with extraordinary properties that provide the opportunity of exploitation in different areas of chemistry and biology. In addition, boron clusters are clinically used in boron neutron capture therapy (BNCT) of tumors. In this paper, a novel, in solid state (solvent free), thermal method for protein modification with boron clusters has been proposed. METHODS The method is based on a cyclic ether ring opening in oxonium adduct of cyclic ether and a boron cluster with nucleophilic centers of the protein. Lysozyme was used as the model protein, and the physicochemical and biological properties of the obtained conjugates were characterized. RESULTS The main residues of modification were identified as arginine-128 and threonine-51. No significant changes in the secondary or tertiary structures of the protein after tethering of the boron cluster were found using mass spectrometry and circular dichroism measurements. However, some changes in the intermolecular interactions and hydrodynamic and catalytic properties were observed. CONCLUSIONS To the best of our knowledge, we have described the first example of an application of cyclic ether ring opening in the oxonium adducts of a boron cluster for protein modification. In addition, a distinctive feature of the proposed approach is performing the reaction in solid state and at elevated temperature. GENERAL SIGNIFICANCE The proposed methodology provides a new route to protein modification with boron clusters and extends the range of innovative molecules available for biological and medical testing.
Collapse
Affiliation(s)
- Tomasz M Goszczyński
- "Neolek" Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, PAS, 12 Rudolf Weigl St., 53-114 Wrocław, Poland.
| | - Konrad Kowalski
- "Neolek" Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, PAS, 12 Rudolf Weigl St., 53-114 Wrocław, Poland
| | - Zbigniew J Leśnikowski
- Laboratory of Molecular Virology and Biological Chemistry, Institute of Medical Biology, PAS, 106 Lodowa St., 93-232 Łódź, Poland.
| | - Janusz Boratyński
- "Neolek" Laboratory of Biomedical Chemistry, Department of Experimental Oncology, Institute of Immunology and Experimental Therapy, PAS, 12 Rudolf Weigl St., 53-114 Wrocław, Poland
| |
Collapse
|
32
|
Ahrens VM, Frank R, Boehnke S, Schütz CL, Hampel G, Iffland DS, Bings NH, Hey-Hawkins E, Beck-Sickinger AG. Receptor-Mediated Uptake of Boron-Rich Neuropeptide Y Analogues for Boron Neutron Capture Therapy. ChemMedChem 2014; 10:164-72. [DOI: 10.1002/cmdc.201402368] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Indexed: 12/31/2022]
|
33
|
Vigorov AI, Demin AM, Nizova IA, Krasnov VP. [The synthesis of RGD peptide derivatives containing glutaric and adipic residues]. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2014; 40:157-65. [PMID: 25895334 DOI: 10.1134/s1068162014020149] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
A method of the synthesis of RGD peptide derivatives containing glutaric or adipic residues linked with α-amino group of L-arginine and allowing carrying out their coupling with other biomolecules and nanoparticles.
Collapse
|
34
|
|
35
|
In search of active RGD peptides: Theoretical study of hydrogen bonding in five-member ring cyclic-RGD isomers. COMPUT THEOR CHEM 2012. [DOI: 10.1016/j.comptc.2012.07.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Masunaga SI, Kimura S, Harada T, Okuda K, Sakurai Y, Tanaka H, Suzuki M, Kondo N, Maruhashi A, Nagasawa H, Ono K. Evaluating the Usefulness of a Novel 10B-Carrier Conjugated With Cyclic RGD Peptide in Boron Neutron Capture Therapy. World J Oncol 2012; 3:103-112. [PMID: 29147290 PMCID: PMC5649788 DOI: 10.4021/wjon477w] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/23/2012] [Indexed: 01/12/2023] Open
Abstract
Background To evaluate the usefulness of a novel 10B-carrier conjugated with an integrin-binding cyclic RGD peptide (GPU-201) in boron neutron capture therapy (BNCT). Methods GPU-201 was synthesized from integrin-binding Arg-Gly-Asp (RGD) consensus sequence of matrix proteins and a 10B cluster 1, 2-dicarba-closo-dodecaborane-10B. Mercaptododecaborate-10B (BSH) dissolved in physiological saline and BSH and GPU-201 dissolved with cyclodextrin (CD) as a solubilizing and dispersing agent were intraperitoneally administered to SCC VII tumor-bearing mice. Then, the 10B concentrations in the tumors and normal tissues were measured by γ-ray spectrometry. Meanwhile, tumor-bearing mice were continuously given 5-bromo-2’-deoxyuridine (BrdU) to label all proliferating (P) cells in the tumors, then treated with GPU-201, BSH-CD, or BSH. Immediately after reactor neutron beam or γ-ray irradiation, during which intratumor 10B concentrations were kept at levels similar to each other, cells from some tumors were isolated and incubated with a cytokinesis blocker. The responses of the Q and total (= P + Q) cell populations were assessed based on the frequency of micronuclei using immunofluorescence staining for BrdU. Results The 10B from BSH was washed away rapidly in all these tissues and the retention of 10B from BSH-CD and GPU-201 was similar except in blood where the 10B concentration from GPU-201 was higher for longer. GPU-201 showed a significantly stronger radio-sensitizing effect under neutron beam irradiation on both total and Q cell populations than any other 10B-carrier. Conclusion A novel 10B-carrier conjugated with an integrin-binding RGD peptide (GPU-201) that sensitized tumor cells more markedly than conventional 10B-carriers may be a promising candidate for use in BNCT. However, its toxicity needs to be tested further.
Collapse
Affiliation(s)
- Shin-Ichiro Masunaga
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Sadaaki Kimura
- Laboratory of Medicinal and Pharmaceutical Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Tomohiro Harada
- Laboratory of Medicinal and Pharmaceutical Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Kensuke Okuda
- Laboratory of Medicinal and Pharmaceutical Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Yoshinori Sakurai
- Radiation Medical Physics, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Hiroki Tanaka
- Radiation Medical Physics, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Minoru Suzuki
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Natsuko Kondo
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Akira Maruhashi
- Radiation Medical Physics, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| | - Hideko Nagasawa
- Laboratory of Medicinal and Pharmaceutical Chemistry, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Koji Ono
- Particle Radiation Oncology Research Center, Research Reactor Institute, Kyoto University, 2-1010, Asashiro-nichi, Kumatori-cho, Sennan-gun, Osaka 590-0494, Japan
| |
Collapse
|
37
|
Savolainen S, Kortesniemi M, Timonen M, Reijonen V, Kuusela L, Uusi-Simola J, Salli E, Koivunoro H, Seppälä T, Lönnroth N, Välimäki P, Hyvönen H, Kotiluoto P, Serén T, Kuronen A, Heikkinen S, Kosunen A, Auterinen I. Boron neutron capture therapy (BNCT) in Finland: technological and physical prospects after 20 years of experiences. Phys Med 2012; 29:233-48. [PMID: 22613369 DOI: 10.1016/j.ejmp.2012.04.008] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/26/2012] [Revised: 04/17/2012] [Accepted: 04/24/2012] [Indexed: 01/18/2023] Open
Abstract
Boron Neutron Capture Therapy (BNCT) is a binary radiotherapy method developed to treat patients with certain malignant tumours. To date, over 300 treatments have been carried out at the Finnish BNCT facility in various on-going and past clinical trials. In this technical review, we discuss our research work in the field of medical physics to form the groundwork for the Finnish BNCT patient treatments, as well as the possibilities to further develop and optimize the method in the future. Accordingly, the following aspects are described: neutron sources, beam dosimetry, treatment planning, boron imaging and determination, and finally the possibilities to detect the efficacy and effects of BNCT on patients.
Collapse
|
38
|
Leonard NM, Brunckova J. One-pot Synthesis of Succinimidyl-4- (N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC). ORG PREP PROCED INT 2012. [DOI: 10.1080/00304948.2012.657938] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Nicholas M. Leonard
- a ADD Organic Operations (Dept. 04KA, Building AP-8B) , Diagnostics Division, Abbott Laboratories , 100 Abbott Park Road, Abbott Park , 60064-6016 , Illinois
| | - Jarmila Brunckova
- a ADD Organic Operations (Dept. 04KA, Building AP-8B) , Diagnostics Division, Abbott Laboratories , 100 Abbott Park Road, Abbott Park , 60064-6016 , Illinois
| |
Collapse
|
39
|
|